Meet the company on a mission to rewrite the cell therapy paradigm from South Texas
While major hurdles are still to be overcome, cell therapies have finally become a reality for certain cancers, and soon…
Partner Content
-
-
How linked data can unlock the full potential of healthcare research
In today’s data-driven healthcare landscape, the ability to link disparate datasets is revolutionizing research and care delivery. As the global…
-
Why the AI hype isn’t the whole story: let’s focus on the benefits
In today’s tech-driven landscape, it seems like every software solution in the clinical industry needs to have some AI angle.…
-
The promise and challenges of the Unified Study Definition Model (USDM)
The clinical trial industry has long recognized the importance of standardization in driving efficiency and ensuring data quality. Efforts by…
-
How ICH E6 (R3) is changing clinical trials
The latest ICH E6 (R3) guidelines could transform how clinical studies are built and operated. The updated ICH E6 (R3)…
-
Exploring AI-powered cell simulations and the launch of the world’s first virtual lab
Artificial intelligence and machine learning (AI/ML) are fundamentally changing the world of drug discovery, enabling researchers to identify the potential…
-
Five considerations when scaling up mAbs in partnership with a CDMO
Scaling up production is a key stage in the lifetime of a monoclonal antibody (mAb), fraught with the risk of…
-
CDMO insights podcast series: Our Experience is Your Strength | Episode #2 Gene Therapy Fill-Finish
“You may design for 12 hours,” says Xufeng Sun, Vice President of Manufacturing Science & Technology at Sharp Sterile, “but…
-
Why global 3PL providers are essential to easing supply chain challenges
With tighter budgets, regulatory challenges, and uncertainty from tariffs, pharmaceutical companies are turning to third-party logistics (3PL) suppliers to deliver…
-
Scaling smart: how small pharma companies can build resilient supply chains
A robust supply chain is the backbone of stable growth, making it a critical area of concern for small pharma…